How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
Cancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patien...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/9/2206 |
| _version_ | 1797505433849561088 |
|---|---|
| author | Yasunori Minami Haruyuki Takaki Koichiro Yamakado Masatoshi Kudo |
| author_facet | Yasunori Minami Haruyuki Takaki Koichiro Yamakado Masatoshi Kudo |
| author_sort | Yasunori Minami |
| collection | DOAJ |
| description | Cancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patients, and resistance mechanisms, including the absence of tumor antigens, have been reported. Thermal ablation involves the induction of irreversible damage to cancer cells by localized heat and may result in the release of tumor antigens. The combination of immunotherapy and thermal ablation is an emerging therapeutic option with enhanced efficacy. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of immuno-oncology (IO) therapy and thermal ablation may be mutually beneficial. In preclinical and clinical studies, the combination of ICI and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. However, evidence for the efficacy of ICI monotherapy combined with thermal ablation is currently insufficient. Therefore, the clinical feasibility of immune response activation by ICI monotherapy combined with thermal ablation may be limited, and thermal ablation may be more compatible with dual ICIs (the IO–IO combination) to induce strong immune responses. |
| first_indexed | 2024-03-10T04:18:31Z |
| format | Article |
| id | doaj.art-f66bab8d5c4b4abe9c2975be4672edf1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:18:31Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f66bab8d5c4b4abe9c2975be4672edf12023-11-23T07:56:24ZengMDPI AGCancers2072-66942022-04-01149220610.3390/cancers14092206How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?Yasunori Minami0Haruyuki Takaki1Koichiro Yamakado2Masatoshi Kudo3Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, JapanDepartment of Radiology, Hyogo College of Medicine, 1-1 Mukogawa Nishinomiya, Nishinomiya 663-8501, JapanDepartment of Radiology, Hyogo College of Medicine, 1-1 Mukogawa Nishinomiya, Nishinomiya 663-8501, JapanDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, JapanCancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patients, and resistance mechanisms, including the absence of tumor antigens, have been reported. Thermal ablation involves the induction of irreversible damage to cancer cells by localized heat and may result in the release of tumor antigens. The combination of immunotherapy and thermal ablation is an emerging therapeutic option with enhanced efficacy. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of immuno-oncology (IO) therapy and thermal ablation may be mutually beneficial. In preclinical and clinical studies, the combination of ICI and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. However, evidence for the efficacy of ICI monotherapy combined with thermal ablation is currently insufficient. Therefore, the clinical feasibility of immune response activation by ICI monotherapy combined with thermal ablation may be limited, and thermal ablation may be more compatible with dual ICIs (the IO–IO combination) to induce strong immune responses.https://www.mdpi.com/2072-6694/14/9/2206immune checkpoint inhibitorimmuno-oncologyinformation disseminationliver metastasisthermal ablationtumor antigen |
| spellingShingle | Yasunori Minami Haruyuki Takaki Koichiro Yamakado Masatoshi Kudo How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? Cancers immune checkpoint inhibitor immuno-oncology information dissemination liver metastasis thermal ablation tumor antigen |
| title | How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? |
| title_full | How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? |
| title_fullStr | How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? |
| title_full_unstemmed | How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? |
| title_short | How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases? |
| title_sort | how compatible are immune checkpoint inhibitors and thermal ablation for liver metastases |
| topic | immune checkpoint inhibitor immuno-oncology information dissemination liver metastasis thermal ablation tumor antigen |
| url | https://www.mdpi.com/2072-6694/14/9/2206 |
| work_keys_str_mv | AT yasunoriminami howcompatibleareimmunecheckpointinhibitorsandthermalablationforlivermetastases AT haruyukitakaki howcompatibleareimmunecheckpointinhibitorsandthermalablationforlivermetastases AT koichiroyamakado howcompatibleareimmunecheckpointinhibitorsandthermalablationforlivermetastases AT masatoshikudo howcompatibleareimmunecheckpointinhibitorsandthermalablationforlivermetastases |